ncreas
express
variou
hydrolyt
enzym
like
peptidas
esteras
proteas
describ
sever
type
human
malign
especi
character
fastgrow
aggress
phenotyp
scientif
literatur
provid
numer
exampl
diagnost
well
therapeut
implic
possibl
relat
chang
respect
peptidas
one
studi
candid
aminopeptidas
n
apn
ec
also
known
microsom
aminopeptidas
aminopeptidas
alanin
aminopeptidas
particlebound
aminopeptidas
zn
depend
membranebound
ectopeptidas
degrad
preferenti
protein
peptid
ntermin
neutral
amino
acid
aminopeptidas
n
although
wide
express
mammalian
cell
associ
differ
aspect
normal
eg
myeloid
progenitor
cell
well
malign
develop
protein
inde
multipl
function
includ
enzymat
regul
peptid
well
characterist
associ
malign
cell
like
tumor
cell
invas
differenti
prolifer
apoptosi
motil
angiogenesi
furthermor
apn
describ
viral
receptor
may
involv
cholesterol
turnov
thu
apn
multipl
function
consequ
design
moonlight
ectoenzym
review
discuss
preval
possibl
function
apn
malign
diseas
well
drugabl
evalu
preclin
vivo
model
also
provid
brief
overview
clinic
trial
focus
apn
aminopeptidas
wide
distribut
enzym
catalyz
cleavag
amino
acid
amino
terminu
protein
peptid
substrat
may
local
subcellular
organel
cytoplasm
membran
compon
monomer
other
assembl
rel
high
mass
kda
subunit
mani
peptidas
zinc
metalloenzym
famili
inhibit
transitionst
analog
bestatin
among
famili
apn
ec
also
known
microsom
aminopeptidas
aminopeptidas
alanin
aminopeptidas
particlebound
aminopeptidas
extens
investig
full
length
apn
consist
amino
acid
short
ntermin
cytoplasm
domain
singl
transmembran
part
larg
cellular
ectodomain
contain
activ
site
aminopeptidas
n
ubiquit
enzym
present
sever
human
organ
tissu
cell
type
describ
multifunct
moonlight
protein
enzymat
well
function
includ
antigen
present
receptor
human
virus
eg
coronavirus
notabl
aminopeptidas
inhibitor
bestatin
actual
design
immunomodul
agent
earli
clinic
trial
see
treatment
section
function
facilit
modul
bioactiv
peptid
respons
influenc
immun
function
major
biolog
event
therebi
provid
treatment
option
mani
kind
diseas
variou
function
apn
includ
biolog
mechan
recent
review
number
outstand
question
rais
interpret
ration
design
apntarget
agent
respect
malign
cell
growth
apn
associ
number
characterist
malign
phenotyp
eg
cell
prolifer
secret
invas
angiogenesi
function
relat
differ
diagnos
discuss
angiogenesi
studi
design
identifi
peptid
home
specif
solid
tumor
pasqualini
cowork
identifi
phage
express
asparagineglycinearginin
ngr
motif
bind
strictli
endothelium
angiogen
blood
vessel
subsequ
studi
reveal
apn
princip
receptor
ngr
peptid
motif
demonstr
receptor
express
exclus
endotheli
cell
angiogen
normal
vasculatur
studi
definit
establish
apn
import
regul
endotheli
morphogenesi
angiogenesi
treatment
anim
apn
inhibitor
significantli
impair
retin
neovascular
chorioallanto
membran
angiogenesi
xenograft
tumor
growth
ii
apn
level
primari
cell
cell
line
upregul
respons
hypoxia
angiogen
growth
factor
signal
regul
capillari
tube
format
angiogenesi
iii
transcript
report
plasmid
contain
apn
proxim
promot
sequenc
significantli
increas
respons
angiogen
signal
regul
express
endogen
gene
vitro
human
tumor
xenograft
iv
function
antagonist
apn
interfer
tube
format
prolifer
primari
vascular
endotheli
cell
suggest
apn
control
endotheli
cell
morphogenesi
result
later
confirm
also
extend
normal
prolifer
endotheli
cell
demonstr
select
express
apn
vascular
endotheli
cell
includ
human
umbil
vein
endotheli
cell
huvec
human
aortic
endotheli
cell
haec
detect
major
normal
cell
tumor
cell
line
inhibit
capillari
tube
format
huvec
matrigel
rna
interfer
rnai
apn
distinct
raseffector
pathway
regul
cytokin
induct
apn
endotheli
cell
phosphoryl
ra
mapk
prerequisit
apn
endotheli
induct
target
play
essenti
role
endotheli
cell
function
experi
identifi
transcript
factor
respons
regul
demonstr
exogen
express
protooncogen
cmaf
potent
activ
transcript
critic
regulatori
region
proxim
promot
atyp
maf
respons
element
high
express
apn
tumor
vessel
may
use
noninvas
vivo
imag
monitor
tumor
growth
angiogenesi
use
ngr
peptid
label
cyanin
dye
cy
success
shown
imag
tumor
growth
nude
mice
apnposit
xenograft
clearli
visual
planar
fluoresc
reflect
imag
fri
fluoresc
mediat
tomographi
fmt
h
inject
fmt
also
allow
quantif
fluorochrom
distribut
deeper
section
tumor
author
suggest
might
promis
strategi
sensit
evalu
tumor
angiogenesi
vivo
besid
apn
two
aminopeptidas
type
methionin
aminopeptidas
adipocytederiv
leucin
aminopeptidas
puromycin
insensit
leucylspecif
aminopeptidas
suggest
involv
process
angiogenesi
prolifer
invas
metastasi
aminopeptidas
inhibitor
bestatin
inhibit
tumorcel
invas
well
aminopeptidas
activ
murin
human
metastat
tumor
cell
effect
attribut
inhibit
apn
inde
monoclon
antibodi
specif
apn
inhibit
invas
human
metastat
tumor
cell
renal
cell
carcinoma
fibrosarcoma
melanoma
reconstitut
basement
membran
matrigel
filter
concentrationdepend
manner
mechan
suggest
direct
inhibit
apn
activ
reduc
degrad
typeiv
collagen
search
cell
surfac
protein
control
cell
motil
angiogenesi
human
colon
cancer
specimen
hashida
cowork
establish
murin
monoclon
antibodi
inhibit
cell
motil
vitro
angiogenesi
epitop
kda
protein
sequenc
analysi
reveal
almost
ident
apn
aminopeptidas
nsilenc
rna
suppress
migrat
huvec
fibronectinco
transwel
membran
reduc
cellular
adhes
matrigel
variou
adhes
molecul
includ
collagen
fibronectin
osteosarcoma
cell
line
mnng
ho
apn
antisens
cdna
transfect
significantli
decreas
invas
potenti
vitro
judg
adhes
migrat
reconsitut
basal
membran
appear
effect
prolifer
motil
collagen
adhes
vivo
condit
reduc
potenc
metastas
lung
shown
experiment
metastasi
assay
nude
mice
undifferenti
thyroid
carcinoma
cell
line
apn
mrna
express
increas
exposur
epiderm
growth
factor
basic
fibroblast
growth
factor
tumor
necrosi
factor
alpha
cell
stabli
transfect
express
vector
apn
show
higher
migrat
rate
author
conclud
apnassoci
downregul
specif
gene
thyroid
carcinoma
cell
import
step
tumor
progress
malign
phenotyp
suggest
import
role
apn
mediat
multimolecular
process
regul
cell
migrat
howev
normal
human
embryon
kidney
cell
express
wt
apn
associ
signific
decreas
prolifer
migrat
also
reduc
anchorageindepend
growth
compar
enzymat
inact
apn
variant
control
appear
due
downregul
mrna
protein
express
chemokin
receptor
inhibit
stromal
cellderiv
factor
sdf
migrat
sever
studi
demonstr
associ
measur
apn
tissu
blood
tumor
patient
discuss
follow
section
inde
solubl
apn
elev
plasma
effus
cancer
patient
compar
healthi
control
also
strong
correl
plasma
apn
tumor
load
suggest
plasma
apn
partli
origin
cell
relat
tumor
tumor
endothelium
apn
activ
express
level
long
time
consid
specif
surfac
antigen
myeloid
cell
relat
neoplasm
first
effort
categor
express
pattern
made
mechtersheim
immunohistochem
examin
nonneoplast
mesenchym
cell
along
benign
malign
mesenchym
tumor
met
use
monoclon
antibodi
tumor
studi
pattern
express
found
mirror
tissu
origin
differenti
express
met
suggest
reflect
special
function
state
neoplasm
dixon
cowork
studi
apn
express
differ
tissu
found
express
breast
epithelium
breast
cancer
sampl
suggest
correl
doxorubicin
resist
aminopeptidas
activ
breast
cancer
tissu
investig
martin
cowork
use
fluorometr
assay
naphtylamid
substrat
compar
adjac
unaffect
tissu
aminopeptidas
activ
includ
solubl
alanylaminopeptidas
ie
sapn
significantli
increas
tumor
anoth
studi
also
investig
activ
apn
cancer
n
noncancer
n
breast
tissu
found
differ
activ
tissu
aminopeptidas
n
also
express
ovarian
cancer
cell
howev
largest
studi
far
patient
primari
laparotomi
secondari
cytoreduct
could
demonstr
relationship
express
clinic
patholog
variabl
express
howev
pronounc
sampl
obtain
primari
laparotomi
compar
sampl
secondari
cytoreduct
p
author
suggest
potenti
treatment
ovarian
cancer
apn
inhibitor
perform
chemotherapi
parallel
firstrelaps
chemotherapi
anoth
studi
quantifi
express
apn
ovarian
cancer
tissu
patient
repres
three
differ
histolog
type
five
patient
immunohistochemistri
ihc
found
associ
histolog
subtyp
apn
express
tumor
cell
observ
patient
serou
mucin
carcinoma
one
clear
cell
carcinoma
patient
sampl
apnposit
blood
vessel
present
stabli
apntransfect
ovarian
cancer
cell
line
chemosensit
growth
vitro
chang
vivo
growth
rate
xenograft
reduc
vascular
architectur
differ
resist
cisplatin
observ
cell
line
data
suggest
correl
also
paclitaxel
sensit
signific
increas
paclitaxelsensit
apnexpress
ovarian
carcinoma
cell
obtain
suppress
enzym
bestatin
sirna
techniqu
furthermor
periton
metastasi
model
use
nude
mice
combin
treatment
paclitaxel
bestatin
caus
synergist
increas
surviv
time
human
colon
cancer
specimen
apn
express
associ
tumor
statu
p
diseasefre
overal
surviv
rate
patient
posit
apn
express
tumor
significantli
lower
patient
apnneg
tumor
studi
oligonucleotid
microarray
monitor
gene
express
leftsid
sporad
colorect
carcinoma
identifi
sever
chromosom
locat
cluster
either
potenti
oncogen
potenti
tumor
suppressor
apn
coincid
high
frequenc
loss
heterozygos
express
apn
studi
thyroid
carcinoma
cell
line
tissu
patient
thyroid
carcinoma
found
undifferenti
anaplast
thyroid
carcinoma
express
apn
differenti
thyroid
carcinoma
ubiquit
express
exemplifi
sever
tumor
type
describ
renal
carcinoma
appear
make
except
case
apn
studi
sampl
renal
clear
cell
carcinoma
activ
protein
level
aminopeptidas
significantli
decreas
compar
adjac
normal
tissu
result
later
confirm
varona
cowork
studi
activ
express
differ
aminopeptidas
rcc
sever
aminopeptidas
found
increas
apn
express
lower
tumor
compar
adjac
tissu
evalu
apn
diagnost
prognost
factor
biomark
studi
apn
measur
patient
breast
thyroid
cancer
patient
benign
tumor
benign
noninflammatori
diseas
aminopeptidas
n
reveal
suffici
sensit
good
specif
suffici
predict
valu
posit
neg
result
overal
good
accuraci
author
suggest
apn
enzym
activ
test
serum
could
use
diagnosi
breast
thyroid
cancer
plasma
level
apn
found
elev
patient
nonsmallcel
lung
cancer
nsclc
patient
control
signific
correl
found
tumor
progress
stage
serum
concentr
r
p
high
serum
apn
n
associ
advanc
stage
p
poor
perform
statu
p
overal
surviv
rate
patient
high
apn
significantli
less
patient
low
apn
n
p
base
multivari
analysi
apn
consid
independ
prognost
factor
patient
nsclc
immunohistochem
studi
case
nsclc
demonstr
correl
express
apn
angiogenesi
r
p
approxim
onethird
patient
apnposit
surviv
significantli
lower
apnneg
tumor
vs
p
anoth
studi
investig
differenti
stain
within
tumor
among
patient
apnposit
tumor
cell
adenocarcinoma
type
stromal
cell
posit
promin
squamou
cell
carcinoma
adenocarcinoma
p
microvessel
densiti
significantli
associ
apnposit
stromal
cell
p
howev
surviv
rate
significantli
differ
group
base
apn
statu
stromal
cell
studi
pancreat
cancer
specimen
n
apn
express
detect
revers
transcriptasepcr
ihc
posit
tumor
respect
aminopeptidas
n
also
significantli
associ
increas
intratumor
microvessel
densiti
although
directli
associ
variou
prognost
factor
median
surviv
time
patient
apn
express
significantli
shorter
patient
without
apn
express
p
multivari
analysi
show
apn
statu
signific
independ
factor
p
contrast
ihc
analysi
patient
gastric
carcinoma
apn
express
neg
associ
lymph
node
metastasi
overal
surviv
rate
patient
neg
apn
express
significantli
lower
patient
posit
apn
express
differ
express
correl
patient
materi
summar
tabl
aminopeptidas
n
clearli
dysregul
human
malign
contribut
neoplast
properti
thu
interfer
apn
express
function
signal
may
lead
develop
novel
anticanc
drug
approach
evalu
tabl
direct
apn
inhibit
relat
structur
function
medicin
chemistri
differ
apn
inhibitor
includ
structur
electron
requir
enzym
activ
site
bind
pocket
review
recent
differ
aminopeptidas
includ
apn
gener
broad
overlap
substrat
specif
inhibitor
expect
specif
exampl
bestatin
inhibit
least
differ
aminopeptidas
ki
lm
aminopeptidas
inhibitor
apninhibit
properti
enter
clinic
trial
anticanc
area
discuss
bestatin
ubenimex
sever
clinic
trial
hematolog
malign
conduct
agent
origin
describ
immunomodul
therapeut
efficaci
surviv
benefit
demonstr
acut
myeloid
leukemia
aml
lymphoma
regard
efficaci
solid
tumor
clinic
studi
conduct
carcinoma
lung
bladder
stomach
head
neck
esophagu
skin
malign
melanoma
sever
trial
nsclc
indic
activ
bestatin
patient
squamou
carcinoma
random
studi
bestatin
patient
nsclc
squamou
cell
carcinoma
adenocarcinoma
type
cancer
demonstr
significantli
prolong
surviv
compar
control
group
without
treatment
patient
squamou
cell
carcinoma
signific
differ
two
group
seen
adenocarcinoma
combin
therapi
bestatin
mg
daili
everi
day
test
random
trial
patient
inoper
primari
lung
cancer
statist
signific
differ
respons
rate
surviv
group
howev
squamou
cell
cancer
respons
observ
bestatin
group
control
group
analysi
includ
cox
proport
hazard
model
reveal
surviv
tend
longer
bestatin
group
median
surviv
week
control
group
median
surviv
week
p
recent
prospect
random
doubleblind
placebocontrol
trial
adjuv
bestatin
mg
daili
oral
year
conduct
patient
complet
resect
stage
squamouscel
lung
carcinoma
four
hundr
two
patient
includ
bestatin
placebo
median
follow
month
overal
surviv
bestatin
group
placebo
group
cancerfre
surviv
bestatin
group
placebo
group
overal
surviv
p
logrank
test
cancerfre
surviv
p
logrank
test
statist
significantli
differ
kaplanmei
analysi
advers
event
observ
either
group
ninetysix
patient
resect
gastric
cancer
random
adjuv
treatment
intraven
mitomycin
c
mmc
plu
oral
administr
tegafur
without
oral
bestatin
mg
daili
surviv
benefit
bestatin
addit
observ
signific
subgroup
stage
iii
iv
patient
posit
histolog
seros
invas
p
logrank
test
moreov
patient
posit
histolog
seros
invas
recurr
periton
dissemin
significantli
suppress
mmc
ft
bestatin
group
patient
nonmetastat
transit
cell
carcinoma
bladder
schedul
fulldos
local
irradi
therapi
gy
adjuv
oral
bestatin
treatment
mg
daili
least
year
posit
effect
outcom
evalu
patient
adjuv
combin
therapi
uft
pyrimidinedion
bestatin
evalu
patient
bladder
cancer
oral
administr
initi
week
postop
continu
year
median
followup
period
day
relapsefre
rate
group
given
uft
alon
group
given
combin
uft
plu
bestatin
patient
solitari
papillari
tumor
relapsefre
rate
significantli
better
uft
plu
bestatin
group
compar
group
uft
alon
furthermor
recent
demonstr
bestatin
enhanc
effect
radiotherapi
ie
act
radiosensit
human
cervic
cancer
vitro
vivo
model
nude
mice
summari
may
conclud
bestatin
repeatedli
studi
treatment
variou
solid
malign
sever
studi
indic
possibl
benefit
addit
treatment
howev
studi
small
record
event
sever
case
posit
result
restrict
subgroup
analys
tosedostat
novel
metalloenzym
inhibitor
convert
pharmacolog
activ
acid
product
insid
cell
potent
inhibitor
number
intracellular
aminopeptidas
exert
antiprolif
effect
rang
tumor
cell
line
vitro
vivo
phase
iii
studi
tosedostat
includ
patient
aml
show
overal
respons
rate
includ
six
patient
complet
respons
prompt
develop
diagnosi
opal
studi
ongo
evalu
efficaci
safeti
tosedostat
aml
oral
bioavail
current
undergo
phase
iii
clinic
investig
treatment
solid
tumor
combin
paclitaxel
myeloid
leukemia
forti
patient
includ
report
phase
trial
acceler
titrat
design
patient
advanc
solid
tumor
administ
daili
commonli
observ
toxic
fatigu
diarrhea
peripher
edema
nausea
dizzi
constip
one
patient
partial
respons
renal
cell
carcinoma
four
patient
stabl
diseas
month
apn
inhibitor
sever
compound
inhibit
apn
preclin
develop
includ
novel
synthet
compound
structur
analog
exampl
bestatin
dimethylaminoethyl
ester
lyp
other
like
curcumin
phenol
natur
product
addit
effect
describ
irrevers
inhibitor
apn
curcumin
current
investig
effect
cancer
patient
sever
clinic
trial
silenc
apn
osteosarcoma
cell
line
mnng
ho
stabli
transfect
express
vector
capabl
express
antisens
transcript
apn
clone
present
reduc
potenc
metastas
lung
shown
experiment
metastasi
assay
nude
mice
use
apn
targetdirect
deliveri
home
ngr
describ
ngr
peptid
asparagineglycinearginin
could
flank
two
cystein
moieti
circular
peptid
cngrc
discov
search
tumor
home
peptid
subsequ
demonstr
apn
ligand
prolifer
endothelium
discuss
detail
ngr
cngrc
motif
use
differ
way
deliv
differ
cytotoxin
apnrich
environ
solid
tumor
given
apn
express
angiogen
endothelium
also
cell
type
mechan
tumorhom
properti
ngr
drug
conjug
may
also
associ
specif
apndepend
sideeffect
howev
studi
express
pattern
apn
normal
neoplast
human
tissu
suggest
differ
apn
form
express
myeloid
cell
epithelia
tumorassoci
blood
vessel
direct
bind
assay
ngrtumor
necrosi
factor
tnf
competit
inhibit
experi
antibodi
show
apn
isoform
express
tumor
blood
vessel
could
function
vascular
receptor
ngr
motif
contrast
apn
express
normal
kidney
myeloid
cell
fail
bind
ngrtnf
find
may
explain
select
tumorhom
properti
ngr
drug
conjug
may
import
implic
develop
vasculartarget
therapi
base
ngr
system
ngrtnf
alpha
conjug
clinic
use
tnf
alpha
anticanc
drug
limit
local
treatment
doselimit
system
toxic
order
increas
therapeut
index
tumor
target
tnf
fusion
protein
tumorhom
peptid
ngr
construct
murin
tnf
fuse
cngrc
peptid
ngrtnf
time
effici
murin
tnf
alon
decreas
tumor
burden
lymphoma
melanoma
anim
model
wherea
toxic
similar
similarli
human
ngrtnf
induc
stronger
antitumor
effect
human
tnf
even
dose
time
lower
fusion
protein
subject
numer
preclin
studi
clearli
demonstr
activ
variou
anim
model
includ
synergist
activ
standard
chemotherapeut
drug
pretreat
ngrtnf
enhanc
respons
cisplatin
doxorubicin
gemcitabin
melphalan
paclitaxel
murin
model
without
appar
increas
toxic
anim
synergist
effect
transient
maxim
synerg
observ
delay
ngrtnf
drug
administr
ngrtnf
increas
vitro
cytotox
chemotherapeut
drug
tumor
cell
suggest
vivo
synerg
depend
ngrtnf
effect
host
cell
rather
tumor
cell
first
clinic
trial
pharmacokinet
plasma
biomark
dynam
contrastenhanc
magnet
reson
imag
evalu
baselin
cycl
patient
enrol
four
doublingdos
level
lg
ngrhtnf
given
intraven
frequent
treatmentrel
toxic
grade
chill
occur
first
infus
seventyf
percent
patient
assess
dcemri
show
decreas
time
k
tran
pronounc
lg
seven
patient
stabl
diseas
median
time
month
includ
colon
cancer
patient
experienc
progressionfre
time
anoth
phase
studi
patient
show
combin
ngrhtnf
plu
doxorubicin
dox
administ
safe
indic
activ
one
partial
respons
stabl
diseas
median
durat
month
also
patient
pretreat
anthracyclin
doselimit
toxic
occur
combin
consid
well
toler
advers
event
relat
ngrhtnf
appar
pharmacokinet
interact
shed
solubl
tnfreceptor
increas
lg
dose
level
lg
ngrhtnf
plu
dox
mg
select
phase
ii
develop
ngrdoxorubicin
conjug
van
hensbergen
cowork
design
dox
deriv
cyclic
cngrc
peptid
coupl
via
hydrolys
spacer
anthracyclinesid
chain
antitumor
activ
test
vitro
nude
mice
bear
human
ovarian
cancer
xenograft
cytotox
effect
demonstr
system
author
conclud
antiprolif
antiangiogen
effect
doxcngrc
like
caus
cytostat
effect
intracellularli
releas
parent
drug
dox
independ
express
activ
ngrcisplatin
conjug
mukhopadhyay
cowork
design
monoand
difunction
platinum
iv
complex
conjug
ngr
peptid
motif
platinum
iv
peptid
complex
nonspecif
amino
acid
peptid
moieti
prepar
control
regard
cytotox
activ
cancer
cell
line
vitro
platinum
iv
ngr
complex
activ
nonspecif
platinumpeptid
control
ngrtruncat
tissu
factor
ttf
conjug
fusion
protein
consist
extracellular
domain
tissu
factor
truncat
tissu
factor
ttf
ngr
motif
express
escherichia
coli
vivo
studi
differ
xenograft
nude
mice
reveal
iv
administr
ttfngr
induc
partial
complet
thrombot
occlus
tumor
vessel
shown
histolog
analysi
signific
tumor
growth
retard
without
appar
sideeffect
human
fibrosarcoma
xenograft
model
magnet
reson
imag
mri
reveal
signific
reduct
tumor
perfus
administr
ttfngr
clinic
firstinman
applic
low
dosag
target
coagul
factor
reveal
good
toler
decreas
tumor
perfus
measur
mri
ngrendostatin
fusion
protein
genet
engin
ngr
motif
introduc
human
endostatin
ngrendostatin
express
yeast
addit
ngrsequenc
amino
terminu
result
strong
bind
inhibit
endotheli
cell
apn
ngrendostatin
show
increas
bind
endotheli
cell
compar
nativ
protein
increas
bind
endostatin
also
coincid
improv
antiangiogen
properti
endostatin
ngr
modif
improv
tumor
local
consequ
effect
inhibit
ovarian
carcinoma
growth
athym
nude
mice
ngrcoat
liposom
micel
canadian
biotech
compani
ambrilia
biopharma
inc
develop
ngrcoat
liposom
carrier
targetdirect
deliveri
cytotox
agent
sirna
http
wwwambriliacom
preclin
data
publish
doxcontain
liposom
tvtdox
sever
xenograft
studi
demonstr
superior
effect
compar
liposom
doxorubicin
without
ngr
cell
prolifer
blood
vessel
densiti
microvessel
area
apoptosi
similar
fashion
wang
cowork
construct
ngrmodifi
docetaxel
dtx
load
pegbpla
polymer
micel
ngrpmdtx
demonstr
quantit
spectrophotofluorometri
qualit
confoc
imag
analysi
ngr
facilit
uptak
micel
tumor
cell
fibrosarcoma
endotheli
cell
huvec
uptak
could
inhibit
free
ngr
balb
c
mice
bear
tumor
xenograft
stronger
antitumor
efficaci
less
bodyweight
chang
shown
ngrpmdtx
group
ngrcoat
nanoparticl
ngrmodif
pegyl
lpd
liposomepolycationdna
nanoparticl
design
effici
deliveri
small
interf
rna
sirna
doxorubicin
tumor
cell
vivo
lpdpegngr
effici
deliv
sirna
cytoplasm
downregul
target
gene
cell
cell
three
daili
inject
mg
kg
cmyc
sirna
formul
lpdpegngr
effect
suppress
cmyc
express
trigger
cellular
apoptosi
tumor
result
partial
tumor
growth
inhibit
doxorubicin
dox
sirna
coformul
lpdpegngr
enhanc
therapeut
effect
observ
ngrgene
therapi
conjug
moffatt
colleagu
develop
polyethylenimin
pei
dna
vector
formul
cngrc
tumorspecif
deliveri
vitro
assess
target
cngrc
peg
pei
dna
vector
carri
betagalactosidas
betag
express
plasmid
show
much
fivefold
increas
transduct
rel
untarget
peg
pei
dnabetag
vector
lung
cancer
fibrosarcoma
bladder
cancer
human
umbil
vein
endotheli
cell
specif
cell
vivo
deliveri
tumor
cell
tumor
endotheli
cell
demonstr
method
may
thu
use
develop
tumortarget
gene
therapi
use
clinic
treatment
cancer
prodrug
concept
sinc
apn
enzymat
capabl
may
use
activ
prodrug
howev
broad
often
overlap
substrat
specif
aminopeptidas
make
true
specif
activ
less
like
melphalan
prodrug
recent
prodrug
demonstr
cleav
apn
releas
constitut
drug
melphalan
free
form
tumor
cell
cytoplasm
close
vicin
relat
apnrich
environ
shown
activ
numer
vitro
preclin
model
superior
compar
melphalan
indic
target
benefit
current
clincal
phase
iiia
trial
two
tumortarget
prodrug
denot
design
cngrc
motif
connect
succin
glutar
linker
respect
prodrug
releas
upon
hydrolysi
lower
cytotox
compar
show
select
cytotox
toward
apn
cell
apn
cell
author
conclud
prodrug
target
apn
caus
tumorcellselect
cytotox
due
releas
rate
could
control
structur
ester
linker
remark
conclus
use
differenti
enzym
express
basi
cancer
therapi
increas
express
variou
hydrolyt
enzym
like
peptidas
esteras
proteas
describ
sever
type
human
malign
especi
character
fastgrow
aggress
phenotyp
enzym
includ
exampl
cathepsin
mmp
plasminogen
activ
high
express
may
relat
metastat
potenti
result
degrad
basement
membran
extracellular
matrix
addit
activ
enzym
growth
factor
proteas
part
metastat
cascad
consequ
may
provid
basi
select
chemotherapi
numer
exampl
literatur
target
mmp
diseas
treatment
complic
fact
mmp
indispens
normal
develop
physiolog
multifunction
possibl
function
redund
contradict
contextdepend
express
activ
complex
reveal
previou
effort
inhibit
mmp
activ
treatment
cancer
patient
yield
unsatisfactori
result
prodrug
concept
also
thoroughli
investig
far
result
mainli
restrict
preclin
studi
exampl
masqueli
cowork
synthes
seri
amino
acid
peptid
deriv
daunorubicin
dnr
serv
prodrug
activ
lysosom
proteas
insid
close
vicin
tumor
cell
similarli
target
cell
high
express
plasminogen
activ
carl
et
al
construct
peptid
conjug
increas
vitro
select
use
three
differ
cytotox
agent
antimetabolit
acivicin
ii
alkyl
phenylenediamin
mustard
iii
anthracyclin
doxorubicin
specif
proteolysistarget
prodrug
may
also
exemplifi
work
denmead
et
al
heptapeptid
conjug
doxorubicin
thapsigargin
studi
deriv
target
activ
serin
prostatespecif
antigen
transmembran
proteas
wide
express
particip
extracellular
proteolysi
degrad
extracellular
matrix
compon
regul
chemokin
activ
releas
membraneanchor
cytokin
cytokin
receptor
adhes
molecul
influenc
cell
function
growth
secret
angiogen
molecul
motil
recent
attent
focus
membran
type
mmp
ectopeptidas
aminopeptidas
n
dipeptidyl
peptidas
iv
angiotensinconvert
enzym
appear
critic
role
angiogenesi
review
describ
preval
possibl
function
apn
malign
primarili
focus
solid
tumor
well
attempt
target
enzym
pharmacolog
conclud
apn
associ
number
characterist
malign
phenotyp
exampl
cell
prolifer
secret
invas
angiogenesi
dysregul
apn
monitor
ihc
tumor
tissu
least
case
serum
analysi
sever
diagnos
appear
posit
correl
clinic
measur
furthermor
use
apn
target
anticanc
therapi
discuss
literatur
present
differ
approach
includ
direct
inhibit
enzym
use
peptid
home
receptor
malign
environ
eg
cngrccoupl
deriv
enzymat
activ
prodrug
compound
class
reach
current
evalu
clinic
trial
bestatin
sever
trial
present
promis
data
studi
small
posit
effect
restrict
subgroup
analysi
other
like
tosedostat
ngrtnf
addit
clinic
data
like
present
within
come
year
apn
associ
sever
characterist
malign
phenotyp
repeatedli
describ
express
overexpress
human
tumor
also
attribut
sever
moonlight
function
may
complic
develop
true
targetspecif
anticanc
drug
futur
tell
harvest
target
regard
prognost
diagnost
measur
well
anticanc
therapi
peter
nygren
rolf
larsson
joachim
gullbo
cofound
minor
sharehold
oncopeptid
ab
small
swedish
research
develop
compani
current
investig
effect
clinic
trial
